cAMP-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer’s Disease

Gregory A. Jicha,1 Charles Weaver,2 Eric Lane,1 Cintia Vianna,1 Yvonne Kress,1 Julia Rockwood,1 and Peter Davies1,2

Departments of 1Pathology and 2Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461

To elucidate the role cAMP-dependent protein kinase (PKA) phosphorylations on tau play in Alzheimer’s disease, we have generated highly specific monoclonal antibodies, CP-3 and PG-5, which recognize the PKA-dependent phosphorylations of ser214 and ser409 in tau respectively. The present study demonstrates by immunohistochemical analysis, CP-3 and PG-5 immunoreactivity with neurofibrillary pathology in both early and advanced Alzheimer’s disease, but not in normal brain tissue and demonstrates that cAMP-dependent protein kinase phosphorylations on tau precede or are coincident with the initial appearance of filamentous aggregates of tau. Studies using heat-stable preparations demonstrate that neither site appears to be phosphorylated to any appreciable extent in normal rodent or human brain. Further analysis demonstrates that the β catalytic subunit of PKA (Cβ), the β II regulatory subunit of PKA (RIIβ), and the 79 kDa A-kinase-anchoring-protein (AKAP79), are tightly associated with the neurofibrillary pathology, positioning cAMP-dependent protein kinase to participate directly in the pathological hyperphosphorylation of tau seen in Alzheimer’s disease.

Key words: tau; Alzheimer’s disease; protein kinase; cAMP; phosphorylation; neurofibrillary pathology

Abnormally hyperphosphorylated tau is the major proteinaceous constituent of the neurofibrillary pathology seen in Alzheimer’s Disease (AD) (Grundke-Iqbal et al., 1986; Wood et al., 1986; Lee et al., 1991; Goedert et al., 1992; Kanemaru et al., 1992). Hyper-phosphorylation of tau, both in vitro and in vivo, has been shown to decrease the affinity of tau for microtubules leading to disruption of the neuronal cytoskeleton and axonal transport mechanisms (Goedert and Jakes, 1990; Drexhcel et al., 1992; Raffaelli et al., 1992; Biernat et al., 1993; for review, see Lee, 1993; Scott et al., 1993; Yoshida and Ihara, 1993; Brandt et al., 1994; Leger et al., 1997; Illenberger et al., 1998). Phosphorylation also inhibits the degradation of tau leading to its gradual accumulation in the cell (Vincent et al., 1994). Certain phosphorylations have also been shown to substantially decrease the electrophoretic mobility of tau by SDS-PAGE analysis over that expected for the accumulation of additional phosphates (presumably the result of conformational alterations in tau) (Scott et al., 1993; Brandt et al., 1994; Leger et al., 1997). Although many neuronal kinases have been implicated as responsible for each of the above functional consequences of tau phosphorylation, the actions of CAMP-dependent protein kinase (PKA) alone can account for all (Scott et al., 1993; Brandt et al., 1994; Leger et al., 1997; Illenberger et al., 1998). As such, a thorough characterization of PKA-dependent phosphorylations on tau is essential for understanding of the pathogenesis of neurofibrillary degeneration seen in AD and other tau-related neurodegenerative disorders.

PKA in the unactivated state exists as a heterotrimer of two catalytic subunits bound to two regulatory subunits. After activation of adenylyl cyclase via extracellular signaling events, ATP is converted to cAMP which then binds to the regulatory subunits releasing the now-activated catalytic subunits of PKA which in turn phosphorylate substrate proteins (for review, see Walsh and Van Patten, 1994). Which proteins become phosphorylated by PKA is largely determined by the subcellular localization of the holoenzyme complex, and this is mediated by a family of proteins termed A-kinase-anchoring proteins (AKAPs) which tether the regulatory subunits of PKA to specific intracellular structures (for review, see Coghlan et al., 1993). Thus, effective signal transduction is dependent on both elevation of intracellular cAMP levels and the localization of PKA in a complex with specific substrates.

Two highly specific monoclonal antibodies, CP-3 and PG-5, have been generated that recognize the PKA-dependent phosphorylations of ser214 and ser409 on tau. This study includes a characterization of these reagents and a demonstration that these phosphorylations are associated with neurofibrillary pathology in AD. Neither site appears to be phosphorylated to any appreciable extent in normal adult rodent or adult human brain. Additional data demonstrate that the β catalytic subunit of PKA (Cβ), the β II regulatory subunit of PKA (RIIβ), and the 79 kDa A-kinase-anchoring-protein (AKAP79) colocalize with and are tightly bound to paired helical filaments (PHF) from AD brain. These data demonstrate that the PKA holoenzyme is uniquely positioned to participate in the neurofibrillary degeneration characteristic of AD, and that PKA-dependent phosphorylations on tau can be used to monitor the pathological conversion of normal tau into an AD-like state.

MATERIALS AND METHODS

Human tissues. Brain tissue was obtained at biopsy and autopsy by the Neuropathology Specimen Bank of Albert Einstein College of Medicine. Autopsy tissues were obtained 3–15 hr after death, and fixed in formalin for at least 3 weeks before sectioning. Biopsy brain tissue was apparently...
normal temporal cortex obtained from patients undergoing temporal lobectomy for intractable epilepsy. For this study, hippocampal tissue from 11 cases of Alzheimer’s disease and four normal individuals was used. Alzheimer cases were selected from cases ranging from Braak stage 2 to stage 5. One of the normal individuals had neurofibrillary tangles confined to the transentorhinal cortex, and was thus classified as Braak stage 1. These cases are representative of a very large number that have been examined with CP-3 and PG-5 for other studies. Vibratome sections of hippocampus, frontal cortex, and temporal cortex from a total of 40 individuals have been investigated with these antibodies. Similar staining is obtained with these antibodies on formalin-fixed, paraffin-embedded tissue sections, and samples from over 120 individual cases have been examined.

Recombinant tau and phosphorylation reactions. Clone httau40 was the generous gift of M. Goedert (Goedert et al., 1989). Clone httau 40 was digested with NdeI and EcoRI, blunted with Klenow, and ligated into SmaI-digested pQE-32 (Qiagen, Hilden, Germany) to produce a histidine-tagged recombinant protein, TauW. TauW was chemically transformed into Escherichia coli strain MC-15 harboring the pREP4 plasmid. Recombinant TauW synthesis was induced, and the protein was purified under non-denaturing conditions according to the manufacturer’s specifications. The eluted sample was then dialyzed overnight in three changes of TBS in preparation for phosphorylation reactions. Protein concentrations were assayed by the method of Bradford, and concentrations were adjusted to 0.2 mg/ml.

PKA and GSK-3 were purchased from Upstate Biotechnology (Lake Placid, NY), and reactions were carried out according to the supplier’s specifications. Recombinant PKC (catalytic subunit) was purchased from Calbiochem (La Jolla, CA). Activated cdk5 was the generous gift of Dr. J. Wang and was reacted as described previously (Paudel et al., 1993). Kinase activity was assessed against recombinant TauW and adjusted to allow for roughly equivalent levels of phosphate incorporation (2.4–3.7 mol P0/mol TauW) with each kinase.

Monoclonal antibodies. CP-3 was generated by immunizing mice with affinity-purified paired helical filaments from AD brain tissue as described previously (Jicha et al., 1999). PG-5 was generated by immunizing mice from 11 cases of Alzheimer’s disease and four normal individuals was used according to manufacturer’s specifications. The anti-PKA-C immunofluorescence was used for the PKA-C specific mouse monoclonal (Ab40) was the generous gift of Dr. J. Erlichman and was used at 1:1000 for Western blot analyses (Licameli et al., 1992). All secondary antibodies were purchased from Life Technologies (Bethesda, MD). Proteins were then transferred to 0.45 μm pore nitrocellulose.

Table 1. Sequences of phospho-tau and non-phospho-tau peptides

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser46(P)</td>
<td>Biotin-KTDAKLKES(P)PLQTPTE</td>
</tr>
<tr>
<td>Ser202(P)</td>
<td>Biotin-KGYSYSGPS(P)PGTPGRS</td>
</tr>
<tr>
<td>Ser214(P)</td>
<td>Biotin-KGSSRTPS(P)LPPTPET</td>
</tr>
<tr>
<td>Thr231</td>
<td>Biotin-KKVVAVVRTTPKSS</td>
</tr>
<tr>
<td>Thr231(P)</td>
<td>Biotin-KKVVAVVRT(P)PPKSS</td>
</tr>
<tr>
<td>Ser235(P)</td>
<td>Biotin-KKAVVVRTPKS(P)PSSAKR</td>
</tr>
<tr>
<td>Ser262(P)</td>
<td>Biotin-KNKVSKGI(P)S(T)ENKHKQ</td>
</tr>
<tr>
<td>Ser356(P)</td>
<td>Biotin-KRVSQKGI(P)LDNTNTHV</td>
</tr>
<tr>
<td>Thr361(P)</td>
<td>Biotin-KIGSDLNIT(P)HVPGGGN</td>
</tr>
<tr>
<td>Ser409</td>
<td>Biotin-KGDTSPRHLSNVSTGSID</td>
</tr>
<tr>
<td>Ser409(P)</td>
<td>Biotin-KGDTSPRHLS(P)NVSTGSID</td>
</tr>
<tr>
<td>Ser412(P)</td>
<td>Biotin-KGDTSPRHLSNV(P)STGSID</td>
</tr>
<tr>
<td>Ser413(P)</td>
<td>Biotin-KGDTSPRHLSNVSS(P)TGSID</td>
</tr>
<tr>
<td>Ser416(P)</td>
<td>Biotin-KGDTSPRHLSNVSTGS(P)ID</td>
</tr>
<tr>
<td>Ser422(P)</td>
<td>Biotin-KGSDMVDS(P)PQOLATLA</td>
</tr>
</tbody>
</table>

CP-13 monoclonal antibody, an IgG1 isotype recognizing phospho-ser202 in tau, were used as positive controls for PHF and phosphorylated tau. TG-5, an IgG1 isotype monoclonal antibody recognizing a phosphorylation-independent primary sequence epitope in tau between amino acids 220–242 was used as a positive control for total tau (Jicha et al., 1997a). CP-3, CP-13, PG-5, PHF-1, and TG-5 were used at a 1:10 dilution. The anti-AKAP79 and anti-calcineurin monoclonal antibodies were purchased from Transduction Laboratories (Lexington, KY) and were used according to manufacturer’s specifications. The anti-PKA-Cb polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and was used according to manufacturer’s specifications. The anti-RIBs-specific mouse monoclonal (Ab40) was the generous gift of Dr. J. Erlichman and was used at 1:1000 for Western blot analyses (Licameli et al., 1992). All secondary antibodies were purchased from Fisher Scientific (Houston, TX) and were used at 1:500 dilution.

Sample preparation and Western blot analyses. Immunofluorescence-purified PHF was prepared as described previously (Jicha et al., 1999). All samples were run on 10% polyacrylamide gels after solubilization in sample buffer and heating at 95°C for 5 min. Molecular weights were verified using prestained markers obtained from Life Technologies (Bethesda, MD). Proteins were then transferred to 0.45 μm pore nitrocellulose.

Figure 1. CP-3 and PG-5 monoclonal antibody specificity. ELISA data demonstrating the specificity of CP-3 for phospho-ser214 and PG-5 for phospho-ser409. Peptide sequences and identification of phosphorylated residues are provided in Table 1.

Figure 2. CP-3 and PG-5 recognize PKA-dependent phosphorylations on tau. The CP-3 and PG-5 epitopes are created by PKA (lane 1) but not PKC (lane 2), Cdk5 (lane 3), or GSK-3b (lane 4) on recombinant tau. A. TG-5 Western blot demonstrating equivalent loading of in vitro phosphorylated recombinant TauW. B. Autoradiogram showing equivalent levels of phosphate incorporation by PKA, PKC, Cdk5, and GSK-3b on recombinant TauW. C. CP-3 Western blot demonstrating epitope creation on recombinant TauW by PKA, not PKC, Cdk5, or GSK-3b. D. PG-5 Western blot demonstrating epitope creation on recombinant TauW by PKA, but not PKC, Cdk5, or GSK-3b.
lose in preparation for Western blot analysis. Blots were blocked in 5% milk in TBS for 30 min and incubated in primary antibody diluted in 5% milk in TBS for 16 hr at 4°C. Horseradish peroxidase-conjugated isotype-specific anti-mouse antibodies were used for detection of primary antibody binding and were incubated for 2 hr at 25°C. Immunostained proteins were visualized by reaction with either 4-chloronapthal (Sigma, St. Louis, MO) 0.5 mg/ml in the presence of H2O2 or with the Pierce (Rockford, IL) Super Signal Ultra chemiluminescence detection kit.

**ELISA analysis.** A series of phospho-tau and non-phospho-tau peptides were synthesized with an N-terminal biotin tag (Table 1). 96-well plates (Nunc, Roskilde, Denmark) were coated with NeutrAvidin (Pierce) for 3 hr at 37°C. The plates were blocked with 2% BSA in TBS for 1 hr at 25°C. Peptides were diluted to 1 μM in 2% BSA in TBS and 50 μl per well was incubated for 1 hr at 25°C. Plates were washed with 0.1% Tween 20 in TBS and incubated with CP-3 or PG-5 for 2 hr at 25°C at a 1:50 dilution in 2% BSA in TBS. Plates were again washed and incubated for 2 hr at 25°C with HRP-labeled goat anti-mouse isotype-specific secondary antibodies at a 1:500 dilution in 2% BSA in TBS. Plates were washed and developed with Bio-Rad (Hercules, CA) ABTS peroxidase substrate. Optical density was measured at 405 nm using an SLT Spectra plate reader (Tecan Technicals US).

**Immunohistochemistry.** Vibratome sections of formalin-fixed AD and normal hippocampus (50-μm-thick) were incubated in 3% (vol/vol) hydrogen peroxide/0.25% Triton X-100 for 30 min at room temperature and washed in 10 mM Tris and 150 mM NaCl, pH 7.4 (TBS). Sections were then incubated in 5% nonfat dry milk (wt/vol) in TBS (TBS–milk) for 1 hr at room temperature to block nonspecific antibody binding and incubated in dilutions of either CP-3, PG-5, or anti-AKAP79 in TBS–milk for 16 hr at 4°C. Tissue sections were then washed with several changes of TBS and reincubated with HRP-labeled isotype-specific secondary antibodies at a 1:500 dilution in TBS–milk for 2 hr at room temperature. Tissue sections that were double-labeled were also incubated with an alkaline phosphatase-conjugated secondary antibody at 1:500 dilution in TBS–milk for 2 hr at room temperature. Tissue sections were then washed with several changes of TBS, and antibody-binding of phosphatase-conjugated secondaries was visualized by reaction with 0.3 mg/ml diaminobenzidine (Sigma) in the presence of H2O2. Double-labeled sections were also incubated with alkaline phosphatase-labeled secondaries and reacted with NBT/BCIP (Pierce). Tissue sections were then mounted on gelatin-coated slides, dehydrated in ethanol and xylene, and coverslipped.

**Electron microscopy.** Immunostained vibratome tissue sections of early AD hippocampus were microdissected, post-fixed in 1% OsO4, dehydrated in ascending ethanol solutions, and embedded in Epon Araldite. Thin sections were prepared and examined unstained using a JEOL Jem 100CX electron microscope.

**RESULTS**

To determine the specificity of both CP-3 and PG-5 for phospho-ser214 and phospho-ser409, respectively, antibody reactivity toward a panel of synthetic phospho-tau and non-phospho-tau peptides (Table 1) was assessed by ELISA (Fig. 1). CP-3 was shown to react with only the peptide containing phospho-ser214, but not with any of the other tau peptides used. PG-5 was shown to react with only the peptide containing phospho-ser409, but not with the equivalent nonphosphorylated peptide or any of the other phospho-tau peptides used.

To demonstrate that the creation of the CP-3 and PG-5 epitopes was dependent on PKA, recombinant tau was reacted...
with either PKA, PKC, Cdk5, or GSK-3β. Although all kinases were able phosphorylate recombinant tau as determined by autoradiographic analysis, only PKA phosphorylation was shown to create the CP-3 and PG-5 epitopes by Western blot (Fig. 2).

Because previous studies have suggested that both ser214 and ser409 are phosphorylated on AD-tau (Hasegawa et al., 1996), immunostaining was performed on both normal and AD hippocampal tissue sections (Fig. 3). Although CP-3 and PG-5 failed to stain tissues from normal elderly controls, both antibodies were shown to react strongly with neurofibrillary tangles, dystrophic neurites, and neuritic elements of plaques in the AD brain. Additionally, PG-5 was shown to react with structures in the white matter of many AD patients that resembles “coiled bodies” or oligodendrocytic tau inclusions more commonly associated with progressive supranuclear palsy (Fig. 3H).

To determine if the accumulation of PKA-dependent phospho-
rations on tau was disease-specific or merely an artifact of the postmortem interval as has been shown for PHF-1 reactivity, CP-3 and PG-5 reactivity was assayed by Western blot against PHF, adult rat, adult mouse, fetal mouse, fetal human, and normal adult human brain heat-stable preparations. As has been shown previously (Matsuo et al., 1994), antibodies recognizing the phosphorylations of ser396/ser404 (PHF-1), ser202 (CP-13), and thr231 (CP-9) exhibit high levels of reactivity against rat, mouse, fetal, and adult human biopsy brain tau (Fig. 4B–D). In contrast, no CP-3 reactivity is evident except with PHF-tau (Fig. 4E). PG-5 also reacts well with PHF-tau and exhibits only minimal reactivity that is limited to staining of faint bands in tau preparations from fetal mouse, fetal human, and adult mouse brain (Fig. 4F). Total tau in these samples is demonstrated by a TG-5 Western blot (Fig. 4A). These data demonstrate that unlike the phospho-tau epitopes recognized by PHF-1 and AT-8, CP-3 and PG-5 reactivity is almost exclusively dependent on an Alzheimer-like disease state in which PKA activity is directed toward the tau molecule.

To determine if the accumulation of PKA-dependent phosphorylations on tau contribute to or are a result of the aggregation of tau into PHF in AD, a series of immunostained vibratome brain sections from early AD cases (Braak stage 2; Braak and Braak, 1991) were either analyzed at the light microscopic level or were microdissected and processed for electron microscopy. Analysis of the CA2 region at the light level demonstrates that PG-5 reacts strongly with isolated neurons that appear both morphologically normal and devoid of overt neurofibrillary tangle formation. Although EM analysis demonstrates that the majority of PG-5 reactivity colocalizes with filamentous aggregates and the surrounding area in the soma of neurons, neurons with few or no filamentous inclusions were also detected (Fig. 5). EM analysis of these neurons demonstrates that the electron-dense DAB precipitate localizes to the periphery of large vesicular bodies in which the initial formation of PHF can be seen. These data demonstrate that the accumulation of PKA-dependent phosphorylations on tau can precede overt PHF formation (Fig. 5D), are accumulated in the immediate vicinity of early PHF aggregates (Fig. 5E), and colocalize with the spread of neurofibrillary pathology throughout the afflicted neuron (Fig. 5F).

Because the discrete localization of PKA-phosphorylated tau by EM analysis suggested that PKA activity was directed toward tau in the early stages of PHF formation, it was important to determine if the PKA holoenzyme complex was also specifically
PKA activation. PKA activity and not merely a result of widespread neuronal dependent phosphorylations on tau in AD are a result of directed tested. These data suggest that the accumulation of PKA-specifically recognize bands in each of the PHF preparations AKAP79-associated protein phosphatase; Coghlan et al., 1995), individual protein kinases with the neurofibrillary pathology seen in AD (Hanger et al., 1992; Baumann et al., 1993; Trojanowski et al., 1993; Wood et al., 1993; Arendt et al., 1995). These data suggest that almost any known neuronal protein kinase system could play a role in the pathological hyperphosphorylation of tau in AD.

Recent evidence, however, has demonstrated that most of the so-called “pathological” phosphorylations on tau are found in freshly frozen adult biopsy tau, and that their “accumulation” in AD brain is an artifact of the postmortem actions of neuronal phosphatases in the normal brain (Matsuo et al., 1994; Hasegawa et al., 1996). These findings have spurred the search for true AD-specific alterations in tau that could contribute to the development of the neurofibrillary pathology characteristic of the disease state. Since these discoveries, several groups have reported on the creation and characterization of true AD-specific antibodies, which fall into three classes: (1) those recognizing conformational alterations in AD-tau (Jicha et al., 1997a,b); (2) those requiring multiple phosphorylations in neighboring sites (Hoffmann et al., 1997); and (3) those recognizing the accumulation of true AD-specific phosphorylations that are independent of the postmortem actions of neuronal phosphatases (Matsuo et al., 1994; Hasegawa et al., 1996).

Recent evidence from our laboratory and others has suggested that PKA-dependent phosphorylations on ser214 and ser409 in tau may be an early step in the conversion of normal tau into an AD-like state (Scott et al., 1993; Brandt et al., 1994; Leger et al., 1997; Illenberger et al., 1998; Jicha et al., 1999). To monitor these potentially pathogenic phosphorylations, two new monoclonal antibodies, recognizing phospho-ser214 (CP-3) and phosphoser409 (PG-5), were created. The phosphorylations of ser214 and ser409 on tau are shown to be exclusively created by PKA in vitro, and their accumulation on brain-derived tau is truly a disease-specific event that precedes and or is coincident with both the initial stages of PHF formation and the spread of neurofibrillary pathology throughout affected neurons in AD. Although previous studies using phosphopeptide mapping strategies have reported
targeted to the sites of PHF formation. To address this issue, a variety of antibodies recognizing constituents of the PKA holoenzyme complex and several different AKAPs were employed. Although many of these antibodies demonstrated no disease-specific alterations in staining patterns (data not shown), one monoclonal antibody recognizing AKAP79 strongly labeled the somatodendritic compartment of neurons in areas vulnerable to the progression of neurofibrillary pathology in AD with only weak labeling of neurons in similar brain regions in normal controls (Fig. 6). Additionally, AKAP79 reactivity appeared to colocalize with neurofibrillary pathology in the hippocampus (CA1) recognized by CP-3 and PG-5 in AD brain tissue by immunocytochemical analysis (Fig. 7). Because of the strong colocalization of AKAP79 immunoreactivity with neurofibrillary pathology in AD, Western blot analysis of five separate immunoaffinity-purified PHF preparations from AD brain homogenates was performed. Figure 8 shows that antibodies to PKA-C, PKA-RIIβ, and AKAP79, but not calcineurin (an AKAP79-associated protein phosphatase; Coghlan et al., 1995), specifically recognize bands in each of the PHF preparations tested. These data suggest that the accumulation of PKA-dependent phosphorylations on tau in AD are a result of directed PKA activity and not merely a result of widespread neuronal PKA activation.

**DISCUSSION**

Although it is widely accepted that hyperphosphorylated tau is the major proteinaceous constituent of the neurofibrillary pathology seen in AD brain, there is a great deal of debate over which, if any, of these phosphorylations are disease-specific (Matsuo et al., 1994) and which neuronal kinase systems are involved in the post-translational modification of tau (for review, see Trojanowski and Lee, 1994). Many studies have shown that a variety of neuronal protein kinases are capable of phosphorylating the tau molecule in vitro (for review, see Trojanowski and Lee, 1994). Several of these studies have also demonstrated colocalization of individual protein kinases with the neurofibrillary pathology seen in AD (Jicha et al., 1997a,b; Brandt et al., 1994; Leger et al., 1997; Illenberger et al., 1998; Jicha et al., 1999). To monitor these potentially pathogenic phosphorylations, two new monoclonal antibodies, recognizing phospho-ser214 (CP-3) and phospho-ser409 (PG-5), were created. The phosphorylations of ser214 and ser409 on tau are shown to be exclusively created by PKA in vitro, and their accumulation on brain-derived tau is truly a disease-specific event that precedes and or is coincident with both the initial stages of PHF formation and the spread of neurofibrillary pathology throughout affected neurons in AD. Although previous studies using phosphopeptide mapping strategies have reported...
that ser214 and ser409 are phosphorylated in both normal adult and fetal tau (Hasegawa et al., 1992; Yoshida and Ihara, 1993; Hanger et al., 1998), these studies have relied on absolute detection of phosphorylated residues in tau and have not determined the relative levels or stoichiometry of these phosphorylations. The present study, using specific monoclonal antibody detection, argues that the levels of phosphate incorporation into these specific sites is very much higher in PHF-tau than in the normal brain. This has previously been shown to be the case for the AD-specific phosphorylation of ser422 in tau by MAP kinase (Hasegawa et al., 1996). Although phospho-ser422 has been identified in normal adult and fetal tau by phosphopeptide mapping strategies (Hasegawa et al., 1992; Yoshida and Ihara, 1993; Hanger et al., 1998), the development of mAb422 has demonstrated that the accumulation of this phosphorylation on tau is indeed a disease-specific event (Hasegawa et al., 1996).

A more recent report has suggested that antibodies recognizing epitopes dependent on the accumulation of multiple neighboring phosphorylations on tau are disease-specific (Hoffmann et al., 1997). Although we agree that accumulations of certain phosphorylations are indicative of the disease state, we note that the AT100 monoclonal antibody used in this previous study is dependent on the phosphorylation of both thr212 and ser214 in tau (Hoffmann et al., 1997), the latter being the phosphorylation recognized by CP-3 in this study. It is possible that the demonstrated specificity of AT100 for the disease state lies solely in its requirement for ser214 phosphorylation and not in its absolute requirement for dual phosphorylation. Nonetheless, it is apparent that the accumulation of phosphorylations specific for the disease state are clues to which signaling cascades might be altered in AD. The present data suggest that the directed activity of PKA toward

**Figure 7.** Double immunocytochemistry in CA1 of the hippocampus with CP-3 (A, C, and E; NBT/BCIP in blue), A, AKAP79; C, PKA-Cβ; E, PKA-RII (DAB in brown). PG-5 staining (B, D, and F; NBT/BCIP in blue); B, AKAP79; D, PKA-Cβ; F, PKA-RIIβ (DAB in brown). Note the colocalization of CP-3 and PG-5 with AKAP79, PKA-RIIβ, and PKA-Cβ-reactive neurons.

**Figure 8.** AKAP79, PKA-RIIβ, and PKA-Cβ but not calcineurin are tightly associated with PHF preparations from four different severe (Braak stage 5) AD cases (lanes 2-5). Lane 1 is a normal adult whole brain homogenate that serves as a positive control for each of the antibodies used.
tau is part of the disruption of signal transduction pathways which lead to the development of neurofibrillary pathology in AD, and that both CP-3 and PG-5 may prove to be valuable tools in the early diagnosis of AD-specific alterations in tau.

It is known that PKA activity is controlled by both intracellular levels of cAMP and by the discrete subcellular localization of the holoenzyme complex (for review, see Coghlan et al., 1993; Walsh and Van Patten, 1994). Two major forms of the PKA holoenzyme complex, Cβ-RIIα and Cβ-RIIβ, are found in the brain regions vulnerable to AD pathology (Cadd and McKnight, 1989; Ludvig et al., 1990; Licameli et al., 1992). The main difference between these complexes is the isoform of the regulatory subunits, RIα and RIIβ, which is the primary determinant of which intracellular proteins (AKAPs) will tether the holoenzyme complex (for review, see Coghlan et al., 1993). RIα has a high affinity for MAP2 (Rubino et al., 1989; Luo et al., 1990), a microtubule-associated protein normally found in the somatodendritic compartment of neurons in which neurofibrillary pathology is found in AD, and RIIβ, which has a high affinity for AKAP79 (Coghlan et al., 1995), a member of the AKAP family that localizes to postsynaptic densities in brain regions vulnerable to AD pathology. Antibodies to PKA-Cβ, PKA-RIIβ, and AKAP79 showed strong associations with neurofibrillary pathology in AD (Figs. 6, 7), whereas RIIα staining exhibited a much weaker association (data not shown). These findings suggest that there is a dysregulation of subcellular localization for PKA-Cβ, PKA-RIIβ, and AKAP79 in AD which may allow for the specific targeting of tau by activated PKA after elevations in cAMP levels. A sequela to these alterations in subcellular localization of the PKA holoenzyme complex in AD is that phosphorylation events downstream of PKA activation, such as those of CREB (a transcription factor involved in learning and memory processes), as well as kainate, glutamate, and β-adrenergic receptors, may not occur in a normal fashion and these signal cascades therefore may fail to function appropriately.

The identification of AKAP79 as a PHF-associated protein, as demonstrated in this study, is interesting in several aspects. First, it should be noted that AKAP79 has previously been shown to be expressed at high levels in cortical regions and hippocampal subfields that are vulnerable to the development of neurofibrillary pathology in AD (Carr et al., 1992; Coghlan et al., 1995; Klauck et al., 1996). It is possible that the presence of AKAP79 in subpopulations of neurons in these regions may be one determinant of which cells develop neurofibrillary pathology. Secondly, it is of interest that in addition to its role in PKA compartmentalization, AKAP79 has been shown to bind and localize calcineurin, a protein phosphatase that has been proposed to function in PKA inactivation. The CP-3 and PG-5 monoclonal antibodies to PKA-Cβ, PKA-RIIβ, and AKAP79, which have been postulated to have gone awry in AD, it is only now becoming clear how or why such a ubiquitous enzyme could participate in the development of neurofibrillary pathology in specific neuronal subpopulations. Although much research remains to be done, the CP-3 and PG-5 monoclonal antibodies may prove to be valuable tools in the identification of AD-specific alterations in cAMP-mediated signal transduction pathways.

REFERENCES


Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric


